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Abstract
Background and Purpose——The RE-SPECT ESUS trial (Randomized, Double-Blind, 
Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral 
Thrombin Inhibitor Dabigatran Etexilate Versus Acetylsalicylic Acid in Patients With Embolic 
Stroke of Undetermined Source) tested the hypothesis that dabigatran would be superior to aspirin 
for the prevention of recurrent stroke in patients with embolic stroke of undetermined source. This 
exploratory subgroup analysis investigates the impact of age, renal function (both predefined), and 
dabigatran dose (post hoc) on the rates of recurrent stroke and major bleeding.
Methods——RE-SPECT ESUS was a multicenter, randomized, double-blind trial of dabigatran 
150 or 110 mg (for patients aged ≥75 years and/or with creatinine clearance 30 to <50 mL/minute) 
twice daily compared with aspirin 100 mg once daily. The primary outcome was recurrent stroke.
Results——The trial, which enrolled 5390 patients from December 2014 to January 2018, did 
not demonstrate superiority of dabigatran versus aspirin for prevention of recurrent stroke in 
patients with embolic stroke of undetermined source. However, among the population qualifying 
for the lower dabigatran dose, the rate of recurrent stroke was reduced with dabigatran versus 
aspirin (7.4% versus 13.0%; hazard ratio, 0.57 [95% CI, 0.39–0.82]; interaction P=0.01). This was 
driven mainly by the subgroup aged ≥75 years (7.8% versus 12.4%; hazard ratio, 0.63 [95% CI, 
0.43–0.94]; interaction P=0.10). Stroke rates tended to be lower with dabigatran versus aspirin 
with declining renal function. Risks for major bleeding were similar between treatments, 
irrespective of renal function, but with a trend for lower bleeding rates with dabigatran versus 
aspirin in older patients.
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Conclusions——In subgroup analyses of RE-SPECT ESUS, dabigatran reduced the rate of 
recurrent stroke compared with aspirin in patients qualifying for the lower dose of dabigatran. 
These results are hypothesis-generating. Aspirin remains the standard antithrombotic treatment for 
patients with embolic stroke of undetermined source.
Registration——URL: https://www.clinicaltrials.gov; Unique identifier: NCT02239120.
Keywords
anticoagulants; atrial fibrillation; cardiovascular disease; risk factors; secondary prevention
Ischemic strokes, according to the TOAST classification (Trial of ORG 10172 in Acute 
Stroke Treatment), are caused by large-artery extracranial or intracranial atherosclerosis, a 
cardiac source of embolism, small-artery occlusion, or other less common etiologies.1 
Twenty to 30% of ischemic strokes are categorized as cryptogenic,2,3 which includes 
patients with an incomplete diagnostic evaluation. The concept of embolic stroke of 
undetermined source (ESUS) was therefore developed based on the exclusion of lacunar 
strokes on brain imaging and on the exclusion of known sources for embolism after a 
required series of diagnostic tests.4,5
We conducted the RE-SPECT ESUS study (Randomized, Double-Blind, Evaluation in 
Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin 
Inhibitor Dabigatran Etexilate Versus Acetylsalicylic Acid in Patients With Embolic Stroke 
of Undetermined Source; NCT02239120).6,7 Our assumption was that oral anticoagulation 
with dabigatran would prevent the recurrence of stroke more effectively than aspirin.
The trial did not demonstrate superiority of dabigatran versus aspirin for prevention of 
recurrent stroke in patients with ESUS. There was no statistically significant difference for 
major bleeding.7 RE-SPECT ESUS was the first Phase III trial in which the dabigatran dose 
was adapted to the assumed risk of bleeding and pharmacokinetic exposure to dabigatran. 
Patients aged ≥75 years and/or with creatinine clearance (CrCl) 30 to <50 mL/minute were 
assigned to the 110 mg twice-daily dose. For stroke prevention in atrial fibrillation (AF), the 
European label for dabigatran recommends lowering the dose in patients aged ≥80 years and 
suggests that dose reduction may be considered based on an individual assessment of 
thromboembolic and bleeding risk in patients aged 75 to 80 years, those with reduced renal 
function (CrCl 30 to <50 mL/minute), or other patients with an increased bleeding risk.8
In RE-SPECT ESUS, we assumed there would be no increase in bleeding risk with 
dabigatran relative to aspirin when administering the lower dabigatran dose to patients who 
were elderly and/or renally impaired compared with the standard dose in patients who were 
younger and/or had normal renal function. In this secondary analysis, we therefore examined 
the impact of age, renal function, and dabigatran dose on the rates of recurrent stroke and 
major bleeding.
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Methods
Data Availability
Qualified scientific and medical researchers may request (via https://vivli.org/) access to de-
identified participant study data with documentation describing the structure and content of 
the datasets. Details are in the Data Supplement.
Study Design
RE-SPECT ESUS was an international, double-blind, randomized trial,6,7 approved by the 
ethics committees at all participating sites. All patients provided written informed consent.
Patients
Patients were aged ≥60 years and diagnosed with an ESUS within the previous 3 months, or 
within the previous 6 months if they had at least 1 additional vascular risk factor, or were 
aged 18 to 59 years with an ESUS within the previous 3 months and at least 1 additional 
vascular risk factor. Diagnosis criteria were described previously.4,7,9 CrCl <30 mL/minute 
was an exclusion criterion.
Treatment
Patients were randomly assigned to dabigatran (150 mg twice daily, or 110 mg twice daily in 
patients aged ≥75 years or with CrCl 30 to <50 mL/ minute) and aspirin placebo, or aspirin 
100 mg once daily and dabigatran placebo (150 or 110 mg twice daily; Figure I in the Data 
Supplement).
Outcomes
The primary efficacy outcome was recurrent stroke assessed in a time-to-event analysis. The 
primary safety outcome was first major bleeding event according to International Society on 
Thrombosis and Haemostasis criteria.10 An independent adjudication committee, blinded to 
treatment assignment, reviewed and classified the events.
Statistical Analysis
We summarized clinical characteristics of patients for the baseline subgroups of dabigatran 
dose, age (<75 or ≥75 years), and CrCl (≥50 or 30 to <50 mL/minute). Age and CrCl were 
predefined subgroup variables, which we analyzed according to categories relevant to doing 
decisions. We also analyzed dabigatran dose subgroups, comparing patients assigned to 110 
and 150 mg with the matching aspirin patients (those meeting the age and CrCl criteria for 
dabigatran 110 and 150 mg, respectively).
All analyses followed an intention-to-treat approach. We used Cox proportional hazard 
models adjusting for stroke or transient ischemic attack before the index stroke (yes/no) to 
analyze outcomes. For the age analysis, we included renal impairment, and for the renal 
function analysis, we included the additional variable of age (with categories as above). We 
provided exploratory P values from treatment-by-subgroup tests for interaction. We also 
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analyzed age and renal function as continuous variables for treatment-by-subgroup 
interaction using analog Cox regression models as described above.
To analyze predictors of major bleeding, we evaluated factors potentially associated with 
bleeding risk in patients diagnosed with ESUS in the combined treatment groups using 
descriptive statistics and Cox proportional hazards regression models. We used a univariable 
Cox regression analysis to identify potential predictors of major bleeding, based on a 
nominal P value <0.05. We built a multivariable Cox regression model based on the set of all 
potential predictors using backward selection (criteria: P<0.1).
Results
Overall, 5390 patients were randomized from December 10, 2014 to January 12, 2018. 
Median follow-up was 19 months. There were no statistically significant differences 
between the dabigatran and aspirin groups for the time to first recurrent stroke or for time to 
first major bleeding in the total study population (Figures 1 and 2).7
Baseline demographics for the subgroups according to treatment and dose assignment are 
shown in the Table, according to age in Table I in the Data Supplement, and CrCl in Table II 
in the Data Supplement.
Of those patients assigned to dabigatran 110 mg (n=611), 88.2% were aged ≥75 years, 
34.9% had CrCl 30 to <50 mL/ minute, and 24.7% were aged ≥75 years with CrCl 30 to <50 
mL/minute. The percentage of patients assigned to dabigatran 110 mg only because of older 
age (ie, age ≥75 years with CrCl ≥50 mL/minute) was 63.5%, and the percentage only 
because of reduced renal function (ie, CrCl <50 mL/minute with age <75 years) was 10.1%. 
Patients assigned to dabigatran 110 or 150 mg (n=2084) doses, respectively, had mean ages 
of 77.9 and 60.6 years, and 49.8% and 33.4% were female (Table). In both treatment groups, 
patients with CrCl 30 to <50 mL/minute were older than those with CrCl ≥50 mL/ minute 
(76.7–76.9 versus 62.8–63.4 years), more often female (50.2%–54.0% versus 35.4%–
35.6%), and had lower mean body mass index (23.7–23.8 versus 27.5–27.6; Table II in the 
Data Supplement).
The effects of age, renal function, or dose on the primary outcome of recurrent stroke in 
patients overall were investigated firstly in a pooled analysis of the dabigatran and aspirin 
treatment groups together. Overall, recurrent stroke occurred in: 10.0% (6.1%/y) of 1030 
patients versus 6.4% (4.1%/y) of 4360 patients aged ≥75 versus <75 years (hazard ratio 
[HR], 1.26 [95% CI, 0.98–1.62]); 13.1% (8.5%/y) of 427 patients with CrCl 30 to <50 mL/
minute versus 6.6% (4.1%/y) of 4955 patients with CrCl ≥50 mL/minute (HR, 1.73 [95% 
CI, 1.26–2.36]); and 10.0% (6.1%/y) of 1157 patients eligible for dabigatran 110 mg twice 
daily versus 6.3% (4.0%/y) of 4233 patients eligible for 150 mg twice daily (regardless of 
actual treatment; HR, 1.52 [95% CI, 1.22–1.89]).
When assessing the treatment effect of dabigatran versus aspirin in the subgroup strata, we 
observed lower rates of recurrent stroke in patients assigned to dabigatran 110 mg twice 
daily versus the corresponding aspirin group (patients aged ≥75 years or with CrCl 30 to <50 
mL/minute; HR, 0.57 [95% CI, 0.39–0.82]) and similar rates in the patients assigned to 
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dabigatran 150 mg twice daily versus their corresponding aspirin group (HR, 1.01 [95% CI, 
0.79–1.28]). In an exploratory analysis based on a nominal alpha level of 5%, these HRs are 
statistically significantly different between the population qualifying for the lower dose of 
dabigatran and the population qualifying for the standard dose; interaction P=0.011 (Figure 
1A). In the subgroup aged ≥75 years, the HR (95% CI) was 0.63 (0.43–0.94) for recurrent 
stroke in dabigatran- versus aspirin-treated patients, and in those <75 years, it was 0.94 
(0.74–1.18); interaction P=0.097 (Figure 1B). For patients with CrCl 30 to <50 mL/minute, 
the HR was 0.63 (0.37–1.07), and for CrCl ≥50, it was 0.90 (0.72–1.11); interaction P=0.209 
(Figure 1C).
Based on the observed trend, we also evaluated age and renal function as continuous 
variables: rates of stroke were reduced for dabigatran versus aspirin in older patients, and 
this effect diminished and was even partly reversed for the younger patients (P for 
interaction of treatment with age=0.045; Figure 3A). Those with lower baseline CrCl also 
had larger treatment benefits with dabigatran versus aspirin than those with higher CrCl who 
had larger treatment benefit with aspirin (P for interaction of treatment with renal 
function=0.012; Figure 3B). The upper limit of the 95% CI crossed the HR of 1.0 at ≈70 
years and at CrCl of ≈75 mL/minute.
Major bleeding in the pooled dabigatran and aspirin treatment groups occurred in: 4.4% 
(2.6%/y) of 1030 patients aged ≥75 versus 2.2% (1.3%/y) of 4360 patients aged <75 years 
(HR, 1.48 [95% CI, 0.99–2.20]); 6.1% (3.7%/y) of 427 patients with CrCl 30 to <50 mL/
minute versus 2.3% (1.4%/y) of 4955 patients with CrCl ≥50 mL/minute (HR, 2.18 [95% 
CI, 1.35–3.51]); and 4.3% (2.6%/y) of 1157 patients eligible for dabigatran 110 mg twice 
daily versus 2.1% (1.3%/y) of 4233 patients eligible for dabigatran 150 mg twice daily 
(regardless of actual treatment; HR, 1.93 [95% CI, 1.37–2.73]). We observed 25 patients 
with gastrointestinal major bleeds receiving dabigatran and 17 receiving aspirin.
The treatment effect of dabigatran versus aspirin on major bleeding events was generally 
consistent with the overall results across the dabigatran dose assignment and renal function 
subgroups, with nonsignificant interaction P values at the 5% level (Figure 2A and 2C). The 
P value for interaction when assessing CrCl as a continuous variable was 0.067. There were 
trends favoring dabigatran for reduction of major bleeding in the older age group and 
favoring aspirin in the younger group (interaction P=0.055 when assessing age as a 
categorical variable [Figure 2B] and 0.020 as a continuous variable).
Table III in the Data Supplement shows the patient characteristics that were considered as 
potential predictors of major bleeding. These are shown for the combined treatment groups 
(overall study population) according to the occurrence of adjudicated major bleeding and 
subsequently according to treatment and the occurrence of adjudicated major bleeding. In 
the combined treatment groups, patients experiencing a major bleed differed from those 
without major bleeds in terms of age (mean age 69.1 versus 64.1 years; P<0.0001) and renal 
function (median CrCl 69.0 versus 83.0 mL/minute; P<0.0001), and by geographic region.
In the univariable Cox regression analysis, based on a nominal P value of 0.05, we identified 
age (HR for 10-year increase, 1.51 [95% CI, 1.28–1.79]; P<0.0001) and renal impairment 
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(HR for 10 units of CrCl [mL/minute] increase=0.86 [95% CI, 0.80–0.91]; P<0.0001) as 
predictors of major bleeding, regardless of treatment. Asian region was also an important 
predictor. Table IV in the Data Supplement shows the full list of variables.
The multivariable Cox regression model derived from backward selection confirmed that age 
was an important predictor for major bleeding. For every 10-year increase in age, the HR for 
a major bleed was 1.56 ([95% CI, 1.31–1.84]; P<0.0001). Other predictors were region 
(Asia versus elsewhere: HR, 1.76 [95% CI, 1.24–2.51]; P=0.0016) and smoking (current or 
ex-smoker versus never smoked: HR, 1.33 [95% CI, 0.95–1.87]; P=0.0990). Univariable 
analysis did not reveal this association between smoking status and occurrence of major 
bleeding, and this result might be an effect of confounding.
Discussion and Summary
In RE-SPECT ESUS, dabigatran did not significantly reduce recurrent stroke versus aspirin 
in ESUS patients and did not show a significant difference in major bleeding.7 In an 
exploratory analysis of patients qualifying for a lower dose of dabigatran (110 mg twice 
daily), who were those aged ≥75 years and/or with reduced renal function, we observed a 
lower risk of recurrent stroke for those randomized to dabigatran versus aspirin, with a 
statistically significantly different effect at a nominal alpha level of 5% than in those 
qualifying for the full dose.
Our original assumption was that patients with ESUS would benefit from anticoagulation 
over antiplatelet therapy, in part because some might have or develop asymptomatic AF. One 
of the most important risk factors for AF is age,11 and after ESUS, AF is detected by 
implantable loop recorders substantially more frequently in elderly patients than in younger 
patients.12 Furthermore, in RE-SPECT ESUS, age was shown to be one of the most 
important predictors for the occurrence of AF during the trial. Patients who developed AF 
had a higher incidence of recurrent stroke than those who did not develop AF.13 This is 
consistent with our observation of a treatment effect of dabigatran over aspirin in the 
subgroup of elderly patients as well as in all patients eligible for the lower dose of 
dabigatran. These patients may be at higher risk of having or developing asymptomatic AF 
over time, thus leading to a greater effect of the anticoagulant versus aspirin in preventing 
recurrent stroke. The RE-SPECT ESUS protocol required a dose reduction of dabigatran in 
patients aged ≥75 years. This group of patients drives the observed effect of the lower dose 
of dabigatran. To gain more insight into the relationship between age and efficacy of 
dabigatran, we analyzed age as a continuous variable. Considering the upper 95% CI of the 
HR (Figure 3A), we observed a reduced risk of recurrent stroke with dabigatran versus 
aspirin for patients aged >70 years.
Among patients with CrCl 30 to <50 mL/minute, there was a trend for an interaction of a 
greater treatment effect with the lower dose of dabigatran over aspirin for preventing 
recurrent stroke. A smaller proportion of patients received the 110 mg twice-daily dose of 
dabigatran only because their CrCl was <50 mL/minute than only because their age was ≥75 
years. Using CrCl as a continuous variable, the upper 95% CI of the HR crossed 1.0 at levels 
of CrCl <75 mL/minute.
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The NAVIGATE ESUS trial (New Approach Rivaroxaban Inhibition of Factor Xa in a 
Global Trial Versus ASA to Prevent Embolism in Embolic Stroke of Undetermined Source) 
used a fixed dose of rivaroxaban but did not show a trend for better efficacy of rivaroxaban 
versus aspirin in elderly or renally impaired patients.14 This might be because the 
observation time was shorter (median 11 months compared with 19 months in RE-SPECT 
ESUS) because of early termination of the trial for futility, or might be related to the dose of 
rivaroxaban (15 mg once daily, rather than 20 mg once daily recommended for stroke 
prevention in patients with AF). Nevertheless, rates of major bleeding were significantly 
higher with rivaroxaban than with aspirin.
In the RE-LY trial, in which patients were randomly assigned to receive fixed dabigatran 
doses, increasing age was an important predictor of major bleeding with dabigatran versus 
warfarin.15,16 The dabigatran labels, except in the United States, recommend a lower dose 
for patients aged ≥80 years, and state a reduced dose should be considered in patients aged 
75 to 80 years.8 Our assumption that bleeding risk would not be increased with dabigatran 
versus aspirin in elderly patients, when the dose was reduced in this group, compared with 
that in younger patients receiving the standard dose, was supported in RE-SPECT ESUS. As 
in the overall trial population, patients aged ≥75 years and/or with CrCl 30 to <50 mL/
minute had similar rates of major bleeding with dabigatran and aspirin. There was a trend 
toward less bleeding with dabigatran versus aspirin in patients aged ≥75 years. However, 
independent of treatment, age and renal function were significant predictors for major 
bleeding in a univariable analysis of predictors. Age remained a significant predictor in the 
multivariate analysis. Although the annualized rate of major bleeding with aspirin in elderly 
patients was higher than reported in some studies, and higher than found in the overall trial, 
it was consistent with previous reports of an increased risk of major bleeding with aspirin in 
older patients.17,18
Of note, the analyses presented are based on an overall clinically neutral trial, which failed 
to show superiority for its primary end point. Two of the subgroup analyses (age and renal 
function) were prespecified, whereas analysis by dabigatran dose was post hoc. The power 
to detect a treatment effect is limited, as the study was designed to test the total effect across 
subgroups, and false-negative and false-positive effects could arise due to testing of multiple 
subgroups. The subgroup analyses presented are therefore hypothesis-generating and should 
not result in modified treatment recommendations for patients with ESUS.
Conclusions
At present, with 2 studies (RE-SPECT ESUS and NAVIGATE ESUS) that failed to show 
superior efficacy of a nonvitamin K antagonist oral anticoagulant compared with aspirin in 
patients with ESUS, the standard of care for secondary stroke prevention remains aspirin.7,14 
Our findings suggest considering a more intense search for cardioembolism or asymptomatic 
AF in ESUS patients, and the elderly in particular,19 and then starting anticoagulation upon 
diagnosis. Also, recruiting patients with a higher probability of developing AF, identified by 
echocardiographic parameters or biomarkers (as in the ARCADIA (Atrial Cardiopathy and 
Antithrombotic Drugs in Prevention After Cryptogenic Stroke) and ATTICUS (Apixaban for 
Treatment of Embolic Stroke of Undetermined Source) trials, which compare apixaban with 
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aspirin in selected ESUS patients),19,20 might be an option to more successfully explore 
superiority for recurrent stroke prevention of a nonvitamin K antagonist oral anticoagulant 
over aspirin in patients with ESUS.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Recurrent stroke with dabigatran vs aspirin by subgroups. Shown by (A) dose assignment, 
(B) age, and (C) renal function subgroups. Creatinine clearance (CrCl) was estimated by 
Cockcroft-Gault equation. Patients aged <75 y and with CrCl ≥50 mL/min were randomly 
assigned to dabigatran 150 mg twice daily plus aspirin placebo or aspirin plus matching 
dabigatran placebo. Patients aged ≥75 y and/or with CrCl 30 to <50 mL/min were randomly 
assigned to dabigatran 110 mg twice daily plus aspirin placebo or aspirin plus matching 
dabigatran placebo.
Diener et al. Page 12
Stroke. Author manuscript; available in PMC 2020 July 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
Major bleeding events with dabigatran vs aspirin by subgroups. Shown by (A) dose 
assignment, (B) age, and (C) renal function subgroups. Creatinine clearance (CrCl) was 
estimated by Cockcroft-Gault equation. Dabigatran dosing, based on age and CrCl, is 
described in Figure 1. HR indicates hazard ratio.
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Figure 3. 
Hazard ratios of recurrent stroke: dabigatran vs aspirin. Shown by (A) age and (B) estimated 
creatinine clearance (CrCl). Cox regression models included factors treatment, prior stroke/
transient ischemic attack, as well as (A) CrCl (≥50 or 30 to <50 mL/min), age, and 
interaction between age and treatment, or (B) age (<75 vs ≥75 y), CrCl, and interaction 
between CrCl and treatment. Patients with missing data for CrCl are excluded from the 
analysis model.
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